Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors
Tóm tắt
Từ khóa
Tài liệu tham khảo
Ålander T, Anden N-E, Grabowska-Anden M (1980) Metoclopramide and sulpiride as selective blocking agents of pre- and postsynaptic dopamine receptors. Naunyn-Schmiedeberg's Arch Pharmacol 312:145–150
Amedro M-J, Couquiaud F. (1986) Evaluation of the effectiveness of tiapride in psychotic anxiety (using the Max Hamilton scale). Semin-Hop 62:981–984
Ansoms C, De Backer-Dierick G, Vereecken JLTM (1977) Sleep disorders in patients with severe mental depression: double-blind placebo-controlled evaluation of the value of pipamperone (Dipiperon®). Acta Psychiatr Scand 55:116–122
Axelsson R, Nilsson A, Christensson E, Björk A (1991) Effects of amperozide in schizophrenia. Psychopharmacology 104:287–292
Balsara JJ, Jadhav JH, Chandorkar AG (1979) Effect of drugs influencing central serotonergic mechanisms on haloperidol-induced catalepsy. Psychopharmacology 62:67–69
Bersani G, Grispini A, Marini S, Pasini A, Valducci M, Ciani N (1990) 5HT2 Antagonist ritanserin in neuroleptic-induced Parkinsonism: a double-blind comparison with orphenadrine and placebo. Clin Neuropharmacol 13:500–506
Bjerkenstedt L (1989) Melperone in the treatment of schizophrenia. Acta Psychiatr Scand Suppl 352:35–39
Borison RL, Sinha D, Haverstock S, McLarnon MC, Diamond BI (1989) Efficacy and safety of tiospirone vs. haloperidol and thioridazine in a double-blind, placebo-controlled trial. Psychopharmacol Bull 25:190–193
Bouthenet ML, Martres MP, Salès N, Schwartz JCh (1987) A detailed mapping of dopamine D-2 receptors in rat central nervous system by autoradiography with [125I]iodosulpride. Neuroscience 20:117–155
Breier A, Wolkowitz OM, Doran AR, Roy A, Boronow J, Hommer DW, Pickar D (1987) Neuroleptic responsivity of negative and positive symptoms in schizophrenia. Am J Psychiatry 144:1549–1555
Brünning G, Kaulen P, Baumgarten G (1987) Quantitative autoradiographic localization of α2-antagonist binding sites in rat brain using [3H]idazoxan. Neurosci Lett 83:333–337
Casey DE (1989) Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 99:S47-S53
Christensen I, Geismar L, Kirkegaard A, Kirkegaard G (1986) Additional studies on side effects of melperone in long-term therapy for 1–20 years in psychiatric patients. Arzneimittelforschung 36:855–860
Christensson E, Björk A (1990) Amperozide: a new pharmacological approach in the treatment of schizophrenia. Pharmacol Toxicol Suppl 1:5–7
Civelli O, Bunzow JR, Grandy DK, Zhuo Q-Y, Van Tol HHM (1991) Molecular biology of the dopamine receptors. Eur J Pharmacol 207:277–286
Claus A, Bollen J, De Cuyper H, Eneman M, Malfroid M, Peuskens J, Heylen S (1992) Risperidone versus haloperidol in the treatment of chronic schizophrenic in patients: a multicentre double-blind comparative study. Acta Psychiatr Scand 85:295–305
Crow TJ, Deakin JFW, Longden A (1977) The nucleus accumbens-possible site of antipsychotic action of neuroleptic drugs? Psychol Med 7:213–221
Darmani NA, Martin BR, Pandey U, Glennon RA (1990) Do functional relationships exist between 5-HT1A and 5-HT2 receptors? Pharmacol Biochem Behav 36:901–906
Deberdt R (1976) Pipamperone (Dipiperon) in the treatment of behaviour disorders. A large-scale multicentre evaluation. Acta Psychiatr Belg 76:157–166
Den Boer JA, Verhoeven WMA, Westenberg GM (1987) Remoxipride, a novel atypical neuroleptic, in the treatment of schizophrenioa. Psychopharmacol Bull 23:206–211
Den Boer JA, Ravelli DP, Huisman J, Ohrvik J, Verhoeven WMA, Westenberg HGM (1990) Double blind comparative study of remoxipride and haloperidol in acute schizophrenic patients. Psychopharmacology 102:76–84
De Paulis T, Kumar Y, Johansson L, Ramsby S, Hall H, Sallemark M, Angeby-Moller K, Ogren SO (1986) Potential neuroleptic agents. 4. Chemistry, behavioral pharmacology, and inhibition of [3H]spiperone binding of 3,5-disubstituted N-[(1-ethyl-2-pyrrolidinyl)methyl]-6-methoxysalicylamines. J Med Chem 29:61–69
De Veaugh-Geiss J, McBain S, Cooksey P, Bell JM (1991) The effects of a novel 5-HT3 antagonist, ondansetron, in schizophrenia: results from uncontrolled trials. In: Meltzer HY (ed) Novel antipsychotic medication. Raven Press, New York
Farde L, Wiesel FA, Jansson P, Uppfeldt G, Wahlen A, Sevall G (1988) An open trial of raclopride in acute schizophrenia. Confirmation of D2-dopamine receptor occupancy by PET. Psychopharmacology 94:1–7
Fargin A, Raymond JR, Regan JW, Cotecchia S, Lefkowitz RJ, Caron MG (1989) Effector coupling mechanisms of the cloned 5-HT1A receptor. J Biol Chem 264:14848–14852
Finney DJ (1962) Probit analysis. Cambridge University Press
Gelders YG, Heylen SLE, Vanden Bussche G, Reyntjens AJM, Janssen PAJ (1990) Pilot clinical investigation of risperidone in the treatment of psychotic patients. Pharmacopsychiatry 23:206–211
Gerlach J, Casey DE (1990) Remoxipride, a new selective D2 antagonist, and haloperidol in cebus monkeys. Prog Neuropsychopharmacol Biol Psychiatry 14:103–112
Gerlach J (1991) New antipsychotics: classification, efficacy, and adverse effects. Schizophr Bull 17:289–309
Grandy DK, Zhang Y, Bouvier C, Zhou Q-Y, Johnson RA, Allen L, Buck K, Bunzow JR, Salon J, Civelli O (1991) Multiple human D5 dopamine receptor genes: a functional receptor and two pseudogenes. Physiol Pharmacol Phys 88:9175–9179
Haase HJ (1954) Über Vorkommen und Deutung des psychomotorischen Parkinsonsyndroms bei Megaphen- bzw. Largactil-Dauerbehandlung. Nervenartzt 25:486
Haase HJ (1978) The purely neuroleptic effects and its relation to the “neuroleptic threshold”. Acta Psychiatr Belg 78:19–36
Haegeman J, Duyck F (1978) A retrospective evaluation of pipamperone (Dipiperon) in the treatment of behavioural deviations in severely mentally handicapped. Acta Psychiatr Belg 78:392–398
Hicks PB (1990) The effect of serotonergic agents on haloperidol-induced catalepsy. Life Sci 47:1609–1615
Janssen PAJ, Niemegeers CJE, Awouters F, Schellekens KHL, Megens AAHP, Meert TF (1988) Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 244:685–693
Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45:789–796
Largent BL, Wikström H, Gundlach AL, Snyder SH (1987) Structural determinants of σ receptor affinity. Mol Pharmacol 32:772–784
Largent BL, Wikström H, Snowman AM, Snyder SH (1988) Novel antipsychotic drugs share high affinity for σ receptors. Eur J Pharmacol 155:345–347
Lesch K-P (1991) 5-HT1A receptor responsivity in anxiety disorders and depression. Prog Neuropsychopharmacol Biol Psychiatry 15:723–733
Leysen JE (1989) Use of 5-HT receptor agonists and antagonists for the characterization of their respective receptor sites. Neuromethods 12:299–350
Leysen JE (1990) Gaps and peculiarities in 5-HT2 receptor studies. Neuropsychopharmacology 3:361–369
Leysen JE, Niemegeers CJE (1985) Neuroleptics. In: Lajtha A (ed) Handbook of neurochemistry. Plenum pp 331–361
Leysen JE, Niemegeers CJE, Tollenaere JP, Laduron PM (1978) Serotonergic component of neuroleptic receptors. Nature 272:168–171
Leysen JE, Gommeren W, Eens A, de Chaffoy de Courcelles D, Stoof JC, Janssen PAJ (1988) Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 247:661–670
Leysen JE, Janssen PMF, Gommeren W, Wynants J, Pauwels PJ, Janssen PAJ (1992) In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone. Mol Pharmacol 41:494–508
Magnusson O, Fowler CJ, Mohringe B, Wijkström A, Ögren S-O (1988) Comparison of the effects of haloperidol, remoxipride and raclopride on “pre”-and postsynaptic dopamine receptors in the rat brain. Naunyn-Schmiedeberg's Arch Pharmacol 337:379–384
Maj J, Mogilnicka E, Przewlocka B (1975) Antagonistic effect of cyproheptadine on neuroleptic-induced catalepsy. Pharmacol Biochem Behav 3:25–27
Meert TF, Janssen PAJ (1991) Ritanserin, a new therapeutic approach for drug abuse. Part 1: Effects on alcohol. Drug Dev Res 24:235–249
Meert TF, Janssen PAJ (1992a) Ritanserin, a new therapeutic approach for drug abuse. Part 2: Effects on cocaine. Drug Dev Res 25:39–53
Meert TF, Janssen PAJ (1992b) Ritanserin, a new therapeutic approach for drug abuse. Part 3 effects on fentanyl and sucrose. Drug Dev Res 25:55–66
Megens AAHP, Voeten J, Rombouts J, Meert ThF, Niemegeers CJE (1987) Behavioral activity of rats measured by a new method based on the piezoelectric principle. Psychopharmacology 93:382–388
Megens AAHP, Awouters FHL, Niemegeers CJE (1988) Differential effects of the new antipsychotic risperidone on large and small motor movements in rats: a comparison with haloperidol. Psychopharmacology 95:493–496
Megens AAHP, Awouters FHL, Niemegeers CJE (1989) Interaction of haloperidol and risperidone (R 64 766) with amphetamine-induced motility changes in rats. Drug Dev Res 23–33
Megens AAHP, Niemegeers CJE, Awouters FHL (1992a) Behavioral disinhibition and depression in amphetaminized rats: a comparison of risperidone, ocaperidone and haloperidol. J Pharmacol Exp Ther 260:160–167
Megens AAHP, Niemegeers CJE, Awouters FHL (1992b) Antipsychotic profile and side-effect liability of haloperidol, risperidone and ocaperidone as predicted from their differential interaction with amphetamine in rats. Drug Dev Res 26:129–145
Meltzer HY, Nash JF (1991) Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev 43:587–604
Meltzer HY, Matsubara S, Lee J-C (1989a) The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 25:390–392
Meltzer HY, Matsubara S, Lee J-C (1989b) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251:238–246
Mertens C (1991) Long-term treatment of chronic schizophrenic patients with risperidone. In: Kane JM (ed) Risperidone major progress in antipsychotic treatment. Oxford Clinical Communications, Oxford, pp 44–48
Mesotten F, Suy E, Pietguin M, Burton P, Heylen S, Gelders Y (1989) Therapeutic effect and safety of increasing dose of risperidone (R 64 766) in psychotic patients. Psychopharmacology 99:445–449
Moore NC, Meyendorff E, Yeragani V, Lewitt PA, Gershon S (1987) Tiaspirone in schizophrenia. J Clin Psychopharmacol 7:98–101
Nemeroff CB, Cain ST (1985) Neurotensin-dopamine interactions in the CNS. TIPS 6:201–205
Nilsson JLG, Carlsson A (1982) Dopamine-receptor agonist with apparent selectivity for autoreceptors: A new principle for antipsychotic action? TIPS 3:322–325
Östreicher EG, Pinto GF (1987) A microcomputer program for fitting enzyme inhibition rate equations. Comput Biol Med 17:53–68
Palacios JM, Hoyer D, Cortés R (1987) α1-Adrenoceptors in the mammalian brain: similar pharmacology but different distribution in rodents and primates. Brain Res 419:65–75
Paxinos G, Watson Ch (1986) The rat brain in stereotoxic coördinates, 2nd edn. Academic Press, Sidney
Pazos A, Palacios JM (1985) Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors. Brain Res 346:205–230
Pazos A, Cortés R, Palacios JM (1985) Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors. Brain Res 346:231–249
Peuskens J (1990) Risperidone, a new approach in the treatment of schizophrenia. In: Stefanis CN, Rabavilas AD, Soldatos CR (eds) Psychiatry: a world perspective. Exerpta Medica, Amsterdam, pp 184–195
Pharmacia LEO Therapeutics AB (1990) Amperozide: the pharmacological profile of a novel antipsychotic agent. Pharmacol Toxicol Suppl 1:3–51
Quirion R, Bowen WD, Itzhak Y, Junien JL, Musacchio JM, Rothman RB, Su T-P, Tam SW, Taylor DP (1992) A proposal for the classification of sigma binding sites. TIPS 13:85–86
Reyntjens A, Gelders YG, Hoppenbrouwers M-LJA, Vanden Bussche G (1986) Thymostenic effects of ritanserin (R 55 667), a centrally acting serotonin-S2 receptor blocker. Drug Dev Res 8:205–211
Richelson E (1984) Neuroleptic affinities for human brain receptors and their use in predicting adverse effects. J Clin Psychiatry 45:331–336
Saller CF, Czupryna MJ, Salama AI (1990) 5-HT2 Receptor blockade by ICI 169,369 and other 5-HT2 antagonists modulates the effects of D-2 dopamine receptor blockade. J Pharmacol Exp Ther 253:1162–1170
Schenk JO, Morocco MT, Ziemba VA (1991) Interactions between the argininyl moieties of neurotensin and the catechol protons of dopamine. J Neurochem 57:1787–1795
Schotte A, Janssen PFM, Megens AAHP, Leysen JE Receptor occupancy by risperidone and ocaperidone in the rat brain, measured ex vivo by quantitative autoradiography. Janssen Pharmaceutica Preclinical Report, R 64 766/36 and R 79 598/15, March 1992
Seeman P (1980) Brain dopamine receptors. Pharmacol Rev 32:229–313
Snyder SH, Greenberg D, Yamamura HI (1974) Antischizophrenic drugs: affinity for muscarinic cholinergic receptor sites in the brain predicts extrapyramidal effects. J Psychiatr Res 11:91–95
Sokoloff P, Giros B, Martres M-P, Bouthenet M-L, Schwartz J-C (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347:146–150
Sokoloff P, Martres M-P, Giros B, Bouthenet M-L, Schwartz J-C (1992) The third dopamine receptor (D3) as a novel target for antipsychotics. Biochem Pharmacol 43:659–666
Svendsen O, Arnt F, Boeck V, Bogeso KP, Christensen AV, Hyttel J, Larsen J-J (1986) The neuropharmacological profile of tefludazine, a potential antipsychotic drug with dopamine and serotonin receptor antagonistic effects. Drug Dev Res 7:35–47
Squelart P, Soravia (1977) Pipamperone (Dipiperon), a useful sedative neuroleptic drug in troublesome chronic psychotic patients. Acta Psychiatr Belg 77:284–293
Tiberi M, Jarvie KR, Silvia C, Falardeau P, Gingrigh JA, Godinot N, Bertrand L, Yang-Feng TL, Fremeau RT, Caron MG (1991) Cloning, molecular characterization, and chromosomal assignment of a gene encoding a second D1 dopamine receptor subtype: differential expression pattern in rat brain compared with the D1A receptor. Neurobiology 88:7491–7495
Uchida D, Honda F, Otsuka M, Satoh Y, Mori J, Ono T, Hitomi M (1979) Pharmacological study of [2-chloro-11-(2-dimethyl-aminoethoxy)dibenzo-[b,f]thiepine] (zotepine), a new neuroleptic drug. Eur J Pharmacol 129:123–130
Van Hemert JCJ (1975) Pipamperone (Dipiperon, R 3345) in troublesome mental retardates. A double-blind, placebo-controlled cross-over study with long-term follow-up. Acta Psychiatr Scand 52:237–245
Van Tol HHM, Bunzow JR, Guan H-C, Sunahara RK, Seeman P, Niznik HB, Civelli O (1990) Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350:610–614
Van Wielinck PS, Leysen JE (1983) Choice of neuroleptics based on in vitro pharmacology. J Drug Res 8:1984–1997
Wadworth AN, Heel RC (1990) Remoxipride: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in schizophrenia. Drugs 40:863–879
Wilk S, Watson E, Stanley ME (1975) Differential sensitivity of two dopaminergic structures in rat brain to haloperidol and to clozapine. J Pharmacol Exp Ther 195:265–270